2 results
Approved WMORecruiting
PART 1Cohort A (METex14 skipping alterations):• To assess the efficacy of tepotinib in subjects with locally advanced or metast. (NSCLC), harboring the METex14 skipping alterations or MET amplif., as per objective response acc. to RECIST v.1.1,…
Approved WMORecruiting
All efficacy and safety objectives will compare enzalutamide plus leuprolide and enzalutamide monotherapyversus placebo plus leuprolide.